End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.74 CNY | -3.94% | -1.17% | -44.81% |
Apr. 26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | China Stocks Fall Ahead of March Economic Data Release | MT |
Business Summary
Number of employees: 181
Managers
Managers | Title | Age | Since |
---|---|---|---|
Xing Hai Li
FOU | Founder | 61 | 13-02-04 |
Yuan Wei Chen
CEO | Chief Executive Officer | 61 | 13-02-04 |
Ze Yan Shi
DFI | Director of Finance/CFO | 43 | 21-11-11 |
Guo Hong
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-14 |
Dai Li
COO | Chief Operating Officer | 43 | 20-09-20 |
Xia Li
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yuan Wei Chen
CEO | Chief Executive Officer | 61 | 13-02-04 |
Xing Hai Li
FOU | Founder | 61 | 13-02-04 |
Yuan Lun Chen
BRD | Director/Board Member | 54 | 20-09-20 |
Dai Li
COO | Chief Operating Officer | 43 | 20-09-20 |
Ya Guang Zheng
BRD | Director/Board Member | 53 | 23-09-14 |
Yu Quan Wei
BRD | Director/Board Member | 65 | 20-09-20 |
Yong Chen Peng
BRD | Director/Board Member | 71 | 20-09-20 |
Hong Qun Ma
BRD | Director/Board Member | 41 | 23-09-14 |
Wen Li
BRD | Director/Board Member | 40 | 23-09-14 |
Jian Hong Lan
CHM | Chairman | 40 | 20-09-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 99,015,598 | 58,691,836 ( 59.28 %) | 0 | 59.28 % |
Company contact information
Hinova Pharmaceuticals, Inc.
4/F, Bldg 1, No. 2-3, Rongyao Bldg 5 Keyuan South Road
610041, Chengdu
+
http://www.hinovapharma.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.81% | 394M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- 688302 Stock
- Company Hinova Pharmaceuticals Inc.